iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Merck-Bristol-Myers' Phase II Trial To Check Hepatitis C Candidates' Combination
 
 
  Monday, April 22, 2013 7:30 am EDT
 
"We are pleased to collaborate with Bristol-Myers Squibb to advance this potential all-oral combination."
 
WHITEHOUSE STATION, N.J.- Merck (NYSE:MRK) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibb's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus (HCV) infection, genotype 1.
 
"In HCV, agreements like this that combine novel investigational candidates are important to evaluate the potential of novel oral regimens early in the development cycle," said Eliav Barr M.D., vice president, Infectious Diseases, Project Leadership and Management, Merck Research Laboratories. "We are pleased to collaborate with Bristol-Myers Squibb to advance this potential all-oral combination."
 
The planned initiation of the Phase II clinical trial follows the completion of a Phase I safety evaluation of the investigational combination regimen. Under the agreement, Merck will conduct the Phase II clinical trial. Further clinical development activities beyond the Phase II study are not covered as part of this agreement. Additional details of the collaboration were not disclosed.
 
About MK-5172
 
MK-5172 is an investigational orally available HCV NS3/4A protease inhibitor currently being evaluated in combination with other approved and investigational medications in Phase II clinical trials. This includes an all oral combination with MK-8742, Merck's investigational orally available HCV NS5A protease inhibitor.
 
Merck's Global Commitment to Development of Hepatitis Therapies
 
Merck is committed to building on its strong legacy in the field of viral hepatitis by continuing to discover, develop and deliver vaccines and medicines to help prevent and treat viral hepatitis. In hepatitis C, company researchers developed the first approved therapy for chronic HCV in 1991 and the first combination therapy in 1998. In addition to ongoing studies for our marketed and investigational medicines for the treatment of chronic HCV, extensive research efforts are underway to develop additional oral therapies for viral hepatitis treatment.
 
About Daclatasvir
 
Daclatasvir is an NS5A replication complex inhibitor that is being extensively studied as a key component of potential direct-acting antiviral (DAA) based hepatitis C treatment regimens. Studied in more than 4,100 patients to date, daclatasvir is in Phase III development.
 
About Merck
 
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside of the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook andYouTube.
 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org